Aisling Capital
Aisling Capital is a healthcare-focused investment firm that invests in companies developing and commercializing pharmaceutical, biotechnology, medical device, diagnostics and services businesses. Since 2000 the firm has raised over $1.8 billion across four funds and takes an active approach—providing capital and strategic, operational and financial support to portfolio companies across private and public structures.
Aisling Capital
New York, New York, United States, North America
Services
Equity and structured financing
Provides equity investments across private and public companies and uses a range of investment structures including seed and venture financings, small-cap public equity investments, structured debt, royalty deals and large-cap leveraged buyouts.
Strategic and operational guidance
Works closely with management teams to determine and execute strategy, identify business opportunities, and address scientific, regulatory, commercial and financial risks.
Board-level involvement and governance
Serves as directors, board members and board observers to provide governance and oversight.
Fundraising and investor relations support
Supports portfolio companies through fundraising activities and investor relations based on the firm's fundraising and capital markets experience.
Equity and structured financing
Provides equity investments across private and public companies and uses a range of investment structures including seed and venture financings, small-cap public equity investments, structured debt, royalty deals and large-cap leveraged buyouts.
Strategic and operational guidance
Works closely with management teams to determine and execute strategy, identify business opportunities, and address scientific, regulatory, commercial and financial risks.
Board-level involvement and governance
Serves as directors, board members and board observers to provide governance and oversight.
Fundraising and investor relations support
Supports portfolio companies through fundraising activities and investor relations based on the firm's fundraising and capital markets experience.
Portfolio
Year invested: 2016; Company status: public; Investment status: current; Location: Malvern, PA
#Biopharma
Year invested: 2015; Company status: public; Investment status: historic; Location: Brisbane, CA
#Biopharma
Year invested: 2013; Company status: acquired; Investment status: historic; Location: Stamford, CT
#Biopharma
Year invested: 2003; Company status: public; Investment status: historic; Location: Durham, NC
#Services
Year invested: 2016; Company status: public; Investment status: historic; Location: New Haven, CT
#Biopharma
Year invested: 2018; Company status: public; Investment status: historic; Location: Plymouth Meeting, PA
#Biopharma
Year invested: 2016; Company status: public; Investment status: current; Location: Malvern, PA
#Biopharma
Year invested: 2015; Company status: public; Investment status: historic; Location: Brisbane, CA
#Biopharma
Year invested: 2013; Company status: acquired; Investment status: historic; Location: Stamford, CT
#Biopharma
Year invested: 2003; Company status: public; Investment status: historic; Location: Durham, NC
#Services
Year invested: 2016; Company status: public; Investment status: historic; Location: New Haven, CT
#Biopharma
Year invested: 2018; Company status: public; Investment status: historic; Location: Plymouth Meeting, PA
#Biopharma